MiNK Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$12.6M | -$11.3M | -$22.9M | -$30.9M | -$28.4M |
| Cash from operations | -$5.9M | -$9.6M | -$15.8M | -$18.9M | -$12.8M |
| Capital expenditure | — | — | $73,561 | $250,046 | $248,983 |
| Free cash flow | — | — | -$15.8M | -$19.1M | -$13.1M |
| Share repurchases | — | — | $0 | — | — |
| Total assets | $14.2M | $5.7M | $4.6M | $21.5M | $40.2M |
Shares outstanding 5.0M · Free float 22.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.